29th Mar 2016 07:00
PuriCore plc
("PuriCore or the "Company")
Grant of Options
29 March 2016 - PuriCore plc (AIM: PURI), announces the grant of share options to Dr. Balkrishan (Simba) Gill, Non-Executive Director, to subscribe for up to 35,000 new ordinary shares of 10p each in the capital of the Company (the "Options").
The Options, granted on 24 March 2016, have an exercise price of 26.25 pence each and a five year term. The Options vest as to half on 24 March 2017 and half on 24 March 2018. Dr. Gill holds no other options over shares in the Company.
-Ends-
Enquiries:
PuriCore plc | +44 (0) 20 3727 1000 |
Alex Martin, Chief Executive Officer Marella Thorell, Chief Financial Officer and Chief Operating Officer |
|
|
|
|
|
|
|
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway / Mo Noonan / Victoria Foster Mitchell |
|
|
|
|
|
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
Aubrey Powell / Jen Boorer / Thomas Smale |
|
About PuriCore
PuriCore is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies, based on its proprietary hypochlorous acid platform technology. The Company has initiated a drug development program based upon its proprietary technology and formulations at high concentrations. The Company believes their formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas such as Dermatology and Ophthalmology, including potential rare disease indications. Currently, the Company serves the Supermarket Retail sector and Wound Care market (as a medical device) utilizing different formulations. For more information, visit Puricore.com.
Related Shares:
RLM.L